Effect of genotypic differences in CYP2C19 status on the cure rates for gastroesophageal reflux disease by lansoplazole

被引：0
|
作者：
Furuta, T [1 ]
Shirai, N [1 ]
Xiao, P [1 ]
Kajimura, M [1 ]
Hanai, H [1 ]
机构：
[1] Hamamatsu Univ Sch Med, Hamamatsu, Shizuoka 43131, Japan
来源：
GASTROENTEROLOGY | 2001年 / 120卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
2203
引用
收藏
页码：A432 / A432
页数：1
相关论文
共 50 条
  • [1] Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole
    Furuta, T
    Shirai, N
    Watanabe, F
    Honda, S
    Takeuchi, K
    Iida, T
    Sato, Y
    Kajimura, M
    Futami, H
    Takayanagi, S
    Yamada, M
    Ohashi, K
    Ishizaki, T
    Hanai, H
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (04) : 453 - 460
  • [2] Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin
    Furuta, T
    Shirai, N
    Takashima, M
    Xiao, F
    Hanai, H
    Nakagawa, K
    Sugimura, H
    Ohashi, K
    Ishizaki, T
    PHARMACOGENETICS, 2001, 11 (04): : 341 - 348
  • [3] CYP2C19 Polymorphism in Patients with Gastroesophageal Reflux Disease - a Pilot Study
    Poniewierka, Elzbieta
    Neubauer, Katarzyna
    Kempinski, Radoslaw
    Strutynska-Karpinska, Marta
    Sadakierska-Chudy, Anna
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2011, 20 (01): : 65 - 69
  • [4] Effect of Genotypic Differences in CYP2C19 and on Cure Rates for Helicobacter pylori Infection by Triple Therapy With Different Proton Pump Inhibitors
    Demir, Kadir
    Ormeci, Asli
    Emrence, Zeliha
    Gokturk, Suut
    Baran, Bulent
    Soyer, Ozlem Mutluay
    Akyuz, Filiz
    Karaca, Cetin
    Besisik, Fatih
    Kaymakoglu, Sabahattin
    Ustek, Duran
    GASTROENTEROLOGY, 2013, 144 (05) : S333 - S333
  • [5] Effects of Helicobacter pylori status and CYP2C19 polymorphism on omeprazole efficacy in patients with gastroesophageal reflux disease
    Akiyama, J
    Fujisawa, T
    Koizuka, H
    Yoshinaga, S
    Serizawa, H
    Tashiro, J
    Kurosaka, K
    Muraoka, A
    Shoda, R
    Tamegai, Y
    Yamato, S
    Matsueda, K
    Uemura, N
    GASTROENTEROLOGY, 2003, 124 (04) : A229 - A229
  • [6] Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin
    Furuta, T
    Shirai, N
    Takashima, M
    Xiao, F
    Hanai, H
    Sugimura, H
    Ohashi, K
    Ishizaki, T
    Kaneko, E
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 158 - 168
  • [7] The effect of genetic differences in CYP2C19 on cure rates for Helicobacter pylori by dual therapy with rabeprazole and amoxicillin
    Furuta, T
    Ohashi, K
    Takashima, M
    Shirai, N
    Kosuge, K
    Ishizaki, T
    Kaneko, E
    GASTROENTEROLOGY, 1999, 116 (04) : A167 - A167
  • [8] Impact of genotypic differences in CYP2C19 status on the eradication of Helicobacter pylori in Caucasian patients
    Schwab, M
    Schaeffeler, E
    Klotz, U
    Treiber, G
    GASTROENTEROLOGY, 2003, 124 (04) : A361 - A361
  • [9] Influence of the Cure Rate of Gastroesophageal Reflux Disease in Relation to CYP2C19 Genotype Among Different Kinds of Proton Pump Inhibitors
    Ichikawa, Hitomi
    Sugimoto, Mitsushige
    Sahara, Shu
    Kagami, Takuma
    Hamaya, Yasushi
    Iwaizumi, Moriya
    Osawa, Satoshi
    Sugimoto, Ken
    Furuta, Takahisa
    GASTROENTEROLOGY, 2016, 150 (04) : S476 - S476
  • [10] Individualized Therapy for Gastroesophageal Reflux Disease Potential Impact of Pharmacogenetic Testing based on CYP2C19
    Furuta, Takahisa
    Sugimoto, Mitsushige
    Shirai, Naohito
    MOLECULAR DIAGNOSIS & THERAPY, 2012, 16 (04) : 223 - 234
12345